Human Cancer-Associated Mutations in the Aα Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in Aα Knock-In and Knockout Mice
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Strong evidence has indicated that protein phosphatase 2A (PP2A) is a tumor suppressor, but a mouse model for testing the tumor suppressor activity was missing. The most abundant forms of trimeric PP2A holoenzyme consist of the scaffolding Aα subunit, one of several regulatory B subunits, and the catalytic Cα subunit. Aα mutations were discovered in a variety of human carcinomas. All carcinoma-associated mutant Aα subunits are defective in binding the B or B and C subunits. Here we describe two knock-in mice expressing cancer-associated Aα point mutants defective in binding B' subunits, one knockout mouse expressing truncated Aα defective in B and C subunit binding, and a floxed mouse for generating conditional Aα knockouts. We found that the cancer-associated Aα mutations increased the incidence of cancer by 50 to 60% in lungs of FVB mice treated with benzopyrene, demonstrating that PP2A acts as a tumor suppressor. We show that the effect of Aα mutation on cancer incidence is dependent on the tumor suppressor p53. The finding that the Aα mutation E64D, which was detected in a human lung carcinoma, increases the lung cancer incidence in mice suggests that this mutation also played a role in the development of the carcinoma in which it was discovered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, recurrent mutation of these residues (for example, P179, R183, S256, and R258) result in marked changes in the PP2A holoenzyme composition in cells (Haesen et al., 2016; O’Connor et al., 2019; Ruediger et al., 2011; Taylor et al., 2019).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Ruediger et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with the observations from Cα KO mice, constitutive KO of Ppp2r1a in two different models resulted in embryonic lethality between E5 and E10.5 [10,36].”
From Physiologic functions of PP2A: Lessons from genetically modified mice (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in an in vivo knockin model of the cancer-associated E64G Aα mutant, defective in B56α and B56δ (and potentially other B56 isoforms) binding [10,93], there was no impact on retina structure and function.”
From Physiologic functions of PP2A: Lessons from genetically modified mice (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More importantly, knockout (KO) studies in mice have revealed that the homozygous deletion of PPP2R1A and PPP2CA is embryonically lethal [ 36 – 38 ].”
From Targeting PP2A in cancer: an underrated option (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For instance, the Aα E64G and E64D mutants, respectively discovered in breast and lung carcinoma [104], were found to be defective in B56α and B56δ binding in vivo [10], and B56γ binding in vitro [93].”
From Physiologic functions of PP2A: Lessons from genetically modified mice (2019) · cites this paper as [10]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159 · cited 8×
“Conversely, overexpression of B reverts SV40-STdependent transformation (7, 8).”
BackgroundResultInfluentialRetractedRepbase Update, a database of eukaryotic repetitive elements
Jurka, J., Kapitonov, V. V., Pavlicek, A., Klonowski, P., Kohany, O., & Walichiewicz, J. (2005) · Cytogenetic and Genome Research · doi:10.1159/000084979 · Cited by 3,370
Janssens, V., & Goris, J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530417 · Cited by 1,902 · cited 2×
“Protein phosphatase 2A (PP2A) plays a role in many fundamental cellular processes, such as signal transduction, DNA repair, transcription, translation, and growth control (15, 24, 26, 43, 77).”
BackgroundHayashi, S., & McMahon, A. P. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0597 · Cited by 1,342 · cited 2×
“receptor (ER) that binds tamoxifen (TM) but not endogenous estrogen (21).”
BackgroundFrequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219 · cited 1×
“In a third ovarian cancer, arginine 182 is mutated to tryptophan (27).”
BackgroundA one-step purification of membrane proteins using a high efficiency immunomatrix.
Schneider, C., Newman, R. A., Sutherland, D. R., Asser, U., & Greaves, M. F. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33889-4 · Cited by 764 · cited 1×
“were coupled to monoclonal antibody 6F9 as described previously (60).”
MethodCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 1×
“Further evidence that PP2A is a tumor suppressor comes from the discovery that the B holoenzyme plays a key role in Myc degradation (2) and from the identification of an inhibitor, CIP2A, which binds to PP2A and Myc, thus preventing PP2A from dephosphorylating Myc at serine 62, a prerequisite for Myc degradation (28).”
BackgroundEnumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612 · cited 3×
“An important discovery was that SV40-ST is required for the transformation of primary human cells in combination with SV40 large T antigen, H-ras, and telomerase (20, 80).”
BackgroundWidespread recombinase expression using FLPeR (Flipper) mice
Farley, F. W., Soriano, P., Steffen, L. S., & Dymecki, S. M. (2000) · genesis · doi:10.1002/1526-968x(200011/12)28:3/4<106::aid-gene30>3.0.co;2-t · Cited by 610 · cited 3×
“The CreER mouse was obtained from The Jackson Laboratory (catalog number 004682).”
MethodInfluentialOkadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter.
Suganuma, M., Fujiki, H., Suguri, H., Yoshizawa, S., Hirota, M., Nakayasu, M., Ojika, M., Wakamatsu, K., Yamada, K., & Sugimura, T. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.6.1768 · Cited by 597 · cited 1×
“The first indication that PP2A might be a tumor suppressor came from the finding that okadaic acid is both a tumor promoter and an inhibitor of PP2A (18, 25, 43, 69, 77).”
BackgroundPallas, D. C., Shahrik, L. K., Martin, B. L., Jaspers, S., Miller, T. B., Brautigan, D. L., & Roberts, T. M. (1990) · Cell · doi:10.1016/0092-8674(90)90726-u · Cited by 573
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523 · cited 1×
“However, since phosphorylation of most sites leads to p53 activation or stabilization (13), dephosphorylation by PP2A would inactivate or destabilize p53, which is incompatible with a PP2A tumor suppressor function.”
BackgroundProtein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513 · cited 2×
“Protein phosphatase 2A (PP2A) plays a role in many fundamental cellular processes, such as signal transduction, DNA repair, transcription, translation, and growth control (15, 24, 26, 43, 77).”
BackgroundSontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., & Mumby, M. (1993) · Cell · doi:10.1016/0092-8674(93)90533-v · Cited by 510 · cited 1×
“This raises the question whether the Ras–mitogenactivated protein kinase–extracellular signal-regulated kinase pathway, which is inhibited by PP2A (64), is upregulated in E64D/ , 5-6/ , and 5-6/E64D mutant mice.”
BackgroundNeviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 476 · cited 1×
“ABL activity by inducing its degradation (46, 50).”
BackgroundCrystal structure of a protein phosphatase 2A heterotrimeric holoenzyme
Cho, U. S., & Xu, W. (2007) · Nature · doi:10.1038/nature05351 · Cited by 459 · cited 1×
“Figure 1 shows a schematic diagram of the B -containing holoenzyme whose structure has been revealed by biochemical analysis (53, 56) and X-ray crystallography (9, 19, 44, 78, 79).”
MethodStructure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 1×
“Figure 1 shows a schematic diagram of the B -containing holoenzyme whose structure has been revealed by biochemical analysis (53, 56) and X-ray crystallography (9, 19, 44, 78, 79).”
MethodGroves, M. R., Hanlon, N., Turowski, P., Hemmings, B. A., & Barford, D. (1999) · Cell · doi:10.1016/s0092-8674(00)80963-0 · Cited by 442 · cited 1×
“Figure 1 shows a schematic diagram of the B -containing holoenzyme whose structure has been revealed by biochemical analysis (53, 56) and X-ray crystallography (9, 19, 44, 78, 79).”
MethodPP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426 · cited 1×
“The first indication that PP2A might be a tumor suppressor came from the finding that okadaic acid is both a tumor promoter and an inhibitor of PP2A (18, 25, 43, 69, 77).”
BackgroundSontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S., & Mumby, M. C. (1996) · Neuron · doi:10.1016/s0896-6273(00)80250-0 · Cited by 391
PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390 · cited 2×
“Protein phosphatase 2A (PP2A) plays a role in many fundamental cellular processes, such as signal transduction, DNA repair, transcription, translation, and growth control (15, 24, 26, 43, 77).”
BackgroundAlterations of the PPP2R1B Gene in Human Lung and Colon Cancer
Wang, S. S., Esplin, E. D., Li, J. L., Huang, L., Gazdar, A., Minna, J., & Evans, G. A. (1998) · Science · doi:10.1126/science.282.5387.284 · Cited by 363
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 2×
“Protein phosphatase 2A (PP2A) plays a role in many fundamental cellular processes, such as signal transduction, DNA repair, transcription, translation, and growth control (15, 24, 26, 43, 77).”
BackgroundShaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 342 · cited 1×
“(71), who demonstrated that elimination of p53 tumor suppressor activity by expression of the dominant negative p53 mutant, dnp53 (61), doubles the lung cancer incidence in FVB FIG.”
BackgroundStructure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins
Xing, Y., Xu, Y., Chen, Y., Jeffrey, P. D., Chao, Y., Lin, Z., Li, Z., Strack, S., Stock, J. B., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.09.025 · Cited by 334 · cited 1×
“Figure 1 shows a schematic diagram of the B -containing holoenzyme whose structure has been revealed by biochemical analysis (53, 56) and X-ray crystallography (9, 19, 44, 78, 79).”
MethodIdentification of specific PP2A complexes involved in human cell transformation
Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., & Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00026-1 · Cited by 325 · cited 3×
“Whether all possible forms of B holoenzymes function as tumor suppressors is an open question, but both B and B holoenzymes have been implicated (2, 8).”
BackgroundResultHaploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
Kwabi-Addo, B., Giri, D., Schmidt, K., Podsypanina, K., Parsons, R., Greenberg, N., & Ittmann, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201167798 · Cited by 323 · cited 1×
“Therefore, PP2A does not fall into the group of classic tumor suppressors, such as Rb, that become dysfunctional only when both alleles are inactivated, but instead belongs to the type of tumor suppressors, such as PTEN, that fail to protect from carcinogenesis when one allele is dysfunctional (4, 31).”
BackgroundTumor Promotion by Inhibitors of ProteinZ Phosphatases 1 and 2A: The Okadaic Acid Class of Compounds
(1993) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60958-6 · Cited by 312 · cited 1×
“The first indication that PP2A might be a tumor suppressor came from the finding that okadaic acid is both a tumor promoter and an inhibitor of PP2A (18, 25, 43, 69, 77).”
BackgroundPP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295 · cited 2×
“Protein phosphatase 2A (PP2A) plays a role in many fundamental cellular processes, such as signal transduction, DNA repair, transcription, translation, and growth control (15, 24, 26, 43, 77).”
BackgroundFeng, J., Tamaskovic, R., Yang, Z., Brazil, D. P., Merlo, A., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404936200 · Cited by 294 · cited 1×
“Importantly, PP2A has been shown to inactivate Akt by dephosphorylating both T308 and S473, leading to reduced MDM2 phosphorylation and increased degradation while p53 accumulates (17, 85).”
BackgroundHuman mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase
Zhao, J. J., Gjoerup, O. V., Subramanian, R. R., Cheng, Y., Chen, W., Roberts, T. M., & Hahn, W. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00088-6 · Cited by 279 · cited 1×
“Additional evidence that PP2A controls the phosphorylation state of Akt has come from studies with SV40-ST and Py-ST, which inhibit T308 and S473 dephosphorylation (1, 3, 81, 83).”
BackgroundActions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits
Silverstein, A. M., Barrow, C. A., Davis, A. J., & Mumby, M. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072071699 · Cited by 276 · cited 2×
“By comparison, knockdown of A levels to less than one-third of the wild-type level causes cell death (7, 33, 63, 67).”
BackgroundInvolvement of PP2A in viral and cellular transformation
Arroyo, J. D., & Hahn, W. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209038 · Cited by 238 · cited 1×
“Additional evidence that PP2A controls the phosphorylation state of Akt has come from studies with SV40-ST and Py-ST, which inhibit T308 and S473 dephosphorylation (1, 3, 81, 83).”
Background(2002) · doi:10.1016/b978-0-12-597951-1.x5000-8 · Cited by 230
Sontag, E., Luangpirom, A., Hladik, C., Mudrak, I., Ogris, E., Speciale, S., & White, C. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.4.287 · Cited by 228 · cited 2×
“particular interest is the abundant microtubule-associated Tau protein, which is phosphorylated at multiple sites (65, 66).”
BackgroundCalin, G. A., di Iasio, M. G., Caprini, E., Vorechovsky, I., Natali, P. G., Sozzi, G., Croce, C. M., Barbanti-Brodano, G., Russo, G., & Negrini, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203389 · Cited by 219
Spontaneous Lesions in Aging FVB/N Mice
Mahler, J. F., Stokes, W., Mann, P. C., Takaoka, M., & Maronpot, R. R. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400606 · Cited by 217 · cited 2×
“(20% incidence at 18 months of age) (36, 71).”
BackgroundAssociation of protein phosphatase 2A with polyoma virus medium tumor antigen.
Walter, G., Ruediger, R., Slaughter, C., & Mumby, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2521 · Cited by 209
Self-citationThe Tumor Suppressor PP2A Aβ Regulates the RalA GTPase
Sablina, A. A., Chen, W., Arroyo, J. D., Corral, L., Hector, M., Bulmer, S. E., DeCaprio, J. A., & Hahn, W. C. (2007) · Cell · doi:10.1016/j.cell.2007.03.047 · Cited by 203
Strack, S., Zaucha, J. A., Ebner, F. F., Colbran, R. J., & Wadzinski, B. E. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980323)392:4<515::aid-cne8>3.0.co;2-3 · Cited by 203 · cited 1×
“8 and 9) is consistent with reports for rat brain (68).”
BackgroundChui, D., Oh-Eda, M., Liao, Y.-F., Panneerselvam, K., Lal, A., Marek, K. W., Freeze, H. H., Moremen, K. W., Fukuda, M. N., & Marth, J. D. (1997) · Cell · doi:10.1016/s0092-8674(00)80322-0 · Cited by 198 · cited 3×
“bled using plasmid pFlox tk, generously provided by Steven Hedrick (10).”
MethodInfluentialMoreno, C. S., Park, S., Nelson, K., Ashby, D., Hubalek, F., Lane, W. S., & Pallas, D. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5257 · Cited by 194 · cited 1×
“The B family has two members, striatin and S/G2 nuclear autoantigen (40).”
BackgroundThe ARF tumor suppressor: Structure, functions and status in cancer
Ozenne, P., Eymin, B., Brambilla, E., & Gazzeri, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25511 · Cited by 183 · cited 1×
“Another pathway that involves PP2A in the control of p53 is the Arf-p53 signaling pathway, in which the tumor suppressor Arf (ADP-ribosylation factor), in response to oncogenes, inhibits MDM2 and thus prevents p53 degradation (48).”
BackgroundKremmer, E., Ohst, K., Kiefer, J., Brewis, N., & Walter, G. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1692 · Cited by 175 · cited 4×
“Monoclonal antibody 6F9 was used, which recognizes the N terminus of A and precipitates all holoenzymes, including B holoenzymes (30).”
BackgroundSelf-citationRuediger, R., Pham, H. T., & Walter, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204059 · Cited by 171 · cited 4×
“Based on previous studies, this truncated protein binds neither B nor C subunits and is functionally equivalent to an A knockout (55).”
BackgroundResultSelf-citationHigh Complexity in the Expression of the B′ Subunit of Protein Phosphatase 2A0
Csortos, C., Zolnierowicz, S., Bakó, E., Durbin, S. D., & DePaoli-Roach, A. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2578 · Cited by 163 · cited 1×
“Consistent with our data, high levels of B mRNA were found by Northern blotting in mouse and rabbit brain (12, 38, 47).”
ResultA truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation
Ito, A., Kataoka, T. R., Watanabe, M., Nishiyama, K., Mazaki, Y., Sabe, H., Kitamura, Y., & Nojima, H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.562 · Cited by 159
Li, H., Cai, X., Shouse, G. P., Piluso, L. G., & Liu, X. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601519 · Cited by 158 · cited 2×
“While these findings strongly support a role of B as tumor suppressor in the human lung, it is puzzling that T55 appears to be human specific with no equivalent site in mouse (32).”
BackgroundMolecular Comparison of Human and Mouse Pulmonary Adenocarcinomas
Malkinson, A. M. (1998) · Experimental Lung Research · doi:10.3109/01902149809087385 · Cited by 152 · cited 1×
“In contrast, loss of p53 tumor suppressor activity is rare in genetically or chemically induced murine lung carcinomas (37).”
BackgroundRuediger, R., Pham, H. T., & Walter, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204279 · Cited by 151
Self-citationCritical Role for Protein Phosphatase 2A Heterotrimers in Mammalian Cell Survival
Strack, S., Cribbs, J. T., & Gomez, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408015200 · Cited by 143 · cited 2×
“By comparison, knockdown of A levels to less than one-third of the wild-type level causes cell death (7, 33, 63, 67).”
BackgroundRuediger, R., Hentz, M., Fait, J., Mumby, M., & Walter, G. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.123-129.1994 · Cited by 142 · cited 2×
“Figure 1 shows a schematic diagram of the B -containing holoenzyme whose structure has been revealed by biochemical analysis (53, 56) and X-ray crystallography (9, 19, 44, 78, 79).”
BackgroundMethodSelf-citationRuediger, R., Roeckel, D., Fait, J., Bergqvist, A., Magnusson, G., & Walter, G. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.4872 · Cited by 136
Self-citationLi, X., Scuderi, A., Letsou, A., & Virshup, D. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3674-3684.2002 · Cited by 135 · cited 2×
“By comparison, knockdown of A levels to less than one-third of the wild-type level causes cell death (7, 33, 63, 67).”
BackgroundCritical Role for SV40 Small-t Antigen in Human Cell Transformation
Yu, J., Boyapati, A., & Rundell, K. (2001) · Virology · doi:10.1006/viro.2001.1204 · Cited by 134 · cited 1×
“An important discovery was that SV40-ST is required for the transformation of primary human cells in combination with SV40 large T antigen, H-ras, and telomerase (20, 80).”
BackgroundProtein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias
Perrotti, D., & Neviani, P. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9119-x · Cited by 127 · cited 1×
“ABL activity by inducing its degradation (46, 50).”
BackgroundHaplo‐insufficiency: a driving force in cancer
Berger, A. H., & Pandolfi, P. P. (2011) · The Journal of Pathology · doi:10.1002/path.2800 · Cited by 124 · cited 1×
“Therefore, PP2A does not fall into the group of classic tumor suppressors, such as Rb, that become dysfunctional only when both alleles are inactivated, but instead belongs to the type of tumor suppressors, such as PTEN, that fail to protect from carcinogenesis when one allele is dysfunctional (4, 31).”
BackgroundHernandez-Boussard, T. M., & Hainaut, P. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106385 · Cited by 121 · cited 2×
“Since mutations of the p53 gene are detected in over 50% of human lung cancers (22), PP2A may only function in the remaining cases with intact p53.”
BackgroundZhang, Z., Liu, Q., Lantry, L. E., Wang, Y., Kelloff, G. J., Anderson, M. W., Wiseman, R. W., Lubet, R. A., & You, M. (2000) · PubMed · Cited by 112
Arnold, H. K., & Sears, R. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9128-9 · Cited by 111 · cited 2×
“Whether all possible forms of B holoenzymes function as tumor suppressors is an open question, but both B and B holoenzymes have been implicated (2, 8).”
BackgroundProtein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner
Andrabi, S., Gjoerup, O. V., Kean, J. A., Roberts, T. M., & Schaffhausen, B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706696104 · Cited by 104 · cited 1×
“Additional evidence that PP2A controls the phosphorylation state of Akt has come from studies with SV40-ST and Py-ST, which inhibit T308 and S473 dephosphorylation (1, 3, 81, 83).”
BackgroundZHOU, J., PHAM, H. T., RUEDIGER, R., & WALTER, G. (2003) · Biochemical Journal · doi:10.1042/bj20021244 · Cited by 95
Self-citationLozano, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001115 · Cited by 94 · cited 1×
“Mouse models are powerful tools for studying the functions of tumor suppressor proteins and their ability to counteract oncogenes (35).”
BackgroundAlterations of the PPP2R1B gene located at 11q23 in human colorectal cancers
Takagi, Y., Futamura, M., Yamaguchi, K., Aoki, S., Takahashi, T., & Saji, S. (2000) · Gut · doi:10.1136/gut.47.2.268 · Cited by 90
Yuan, H., Veldman, T., Rundell, K., & Schlegel, R. (2002) · Journal of Virology · doi:10.1128/jvi.76.21.10685-10691.2002 · Cited by 84
Li, X., & Virshup, D. M. (2002) · European Journal of Biochemistry · doi:10.1046/j.0014-2956.2001.02680.x · Cited by 83 · cited 2×
“However, there is evidence that this is likely the case, because the central A binding region in all B subunit isoforms is highly conserved (34), suggesting that A mutations that affect binding of one B isoform will affect all isoforms (this does not exclude that the binding affinities may differ between B isoforms).”
BackgroundMass, M. J., Ross, J. A., Nesnow, S., Jeffers, A. J., Nelson, G. B., Galati, A. J., & Stoner, G. D. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940080309 · Cited by 70 · cited 1×
“Furthermore, it has been shown that the K-ras codon 12 mutation is the most frequent mutation observed in benzopyrene-induced carcinomas (39).”
BackgroundSignaling Pathways in Liver Diseases
Dufour, J., Trautwein, C., Graf, R., & Clavien, P. (2005) · Springer eBooks · doi:10.1007/b138739 · Cited by 70
Wang, Y., Zhang, Z., Kastens, E., Lubet, R. A., & You, M. (2003) · PubMed · Cited by 66
Mumby, M. (2007) · ACS Chemical Biology · doi:10.1021/cb700021z · Cited by 66 · cited 1×
“Figure 1 shows a schematic diagram of the B -containing holoenzyme whose structure has been revealed by biochemical analysis (53, 56) and X-ray crystallography (9, 19, 44, 78, 79).”
MethodColella, S., Ohgaki, H., Ruediger, R., Yang, F., Nakamura, M., Fujisawa, H., Kleihues, P., & Walter, G. (2001) · International Journal of Cancer · doi:10.1002/ijc.1423 · Cited by 59 · cited 1×
“We reported a 10-fold reduced expression of A in 43% of primary human gliomas, suggesting that PP2A might be a tumor suppressor in glial cells (11).”
BackgroundSelf-citationMartens, E., Stevens, I., Janssens, V., Vermeesch, J., Götz, J., Goris, J., & Van Hoof, C. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.12.047 · Cited by 57 · cited 1×
“Consistent with our data, high levels of B mRNA were found by Northern blotting in mouse and rabbit brain (12, 38, 47).”
ResultRundell, K., Major, E. O., & Lampert, M. (1981) · Journal of Virology · doi:10.1128/jvi.37.3.1090-1093.1981 · Cited by 52
Shouse, G. P., Nobumori, Y., & Liu, X. (2010) · Oncogene · doi:10.1038/onc.2010.161 · Cited by 49 · cited 1×
“Furthermore, a B point mutation was discovered in a human lung cancer, which is located in this p53 binding region and renders the B holoenzyme inactive in T55 dephosphorylation and p53 transcriptional activation (62).”
BackgroundBinding Specificity of Protein Phosphatase 2A Core Enzyme for Regulatory B Subunits and T Antigens
Ruediger, R., Fields, K., & Walter, G. (1999) · Journal of Virology · doi:10.1128/jvi.73.1.839-842.1999 · Cited by 48 · cited 2×
“We previously demonstrated that two artificial R183 mutations, R183A and R183E, render the A subunit highly defective in binding B , B , and B /PR72 (52).”
BackgroundSelf-citationProtein phosphatases and DNA tumor viruses: transformation through the back door?
Mumby, M. C., & Walter, G. (1991) · Cell Regulation · doi:10.1091/mbc.2.8.589 · Cited by 46
Self-citationDilated cardiomyopathy in transgenic mice expressing a mutant A subunit of protein phosphatase 2A
Brewis, N., Ohst, K., Fields, K., Rapacciuolo, A., Chou, D., Bloor, C., Dillmann, W., Rockman, H., & Walter, G. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h1307 · Cited by 46 · cited 1×
“Both forms coexist in cultured cells and in tissue (5, 30, 42).”
BackgroundSelf-citationRole for PP2A in ARF signaling to p53
Moule, M. G., Collins, C. H., McCormick, F., & Fried, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405533101 · Cited by 37 · cited 1×
“That PP2A has a positive effect on p53 in this pathway was demonstrated by the finding that inhibition of PP2A by Py-ST prevents Arf-mediated activation of p53 (41).”
BackgroundWang, Y., Zhang, Z., Lubet, R. A., & You, M. (2004) · Oncogene · doi:10.1038/sj.onc.1208390 · Cited by 32 · cited 1×
“Nevertheless, mice have been a useful model for investigating the role of p53 in lung carcinogenesis (71, 75, 76, 82).”
BackgroundDeichmann, M., Polychronidis, M., Wacker, J., Thome, M., & Näher, H. (2001) · Melanoma Research · doi:10.1097/00008390-200112000-00004 · Cited by 30 · cited 1×
“was found in a human melanoma (14), and a truncated form of”
BackgroundA New Role for Protein Methylation: Switching Partners at the Phosphatase Ball
Mumby, M. (2001) · Science's STKE · doi:10.1126/stke.2001.79.pe1 · Cited by 28
Tchou-Wong, K.-M., Jiang, Y., Yee, H. T., LaRosa, J., Lee, T. C., Pellicer, À., Jagirdar, J. S., Gordon, T., Goldberg, J. D., & Rom, W. N. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.27.2.4799 · Cited by 26 · cited 5×
“(20% incidence at 18 months of age) (36, 71).”
BackgroundInfluentialTsao, C. C., Nica, A. F., Kurinna, S. M., Jiffar, T., Mumby, M. C., & Ruvolo, P. P. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4737 · Cited by 26 · cited 1×
“, the A subunit) leads to ablation of the other types (B and C) (33, 63, 67, 72).”
BackgroundAn inbred 129SvEv GFPCre transgenic mouse that deletes loxP-flanked genes in all tissues
Scheel, J. R., Garrett, L. J., Allen, D. M., Carter, T. A., Randolph‐Moore, L., Gambello, M. J., Gage, F. H., Wynshaw-Boris, A. J., & Barlow, C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng057 · Cited by 18
Ortega-Lázaro, J. C., & del Mazo, J. (2003) · Cytogenetic and Genome Research · doi:10.1159/000076823 · Cited by 11 · cited 1×
“Consistent with our data, high levels of B mRNA were found by Northern blotting in mouse and rabbit brain (12, 38, 47).”
ResultRole of PKB/Akt in Liver Diseases
Zhuravleva, E., Tschopp, O., & Hemmings, B. A. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_16 · Cited by 11 · cited 1×
“Importantly, PP2A has been shown to inactivate Akt by dephosphorylating both T308 and S473, leading to reduced MDM2 phosphorylation and increased degradation while p53 accumulates (17, 85).”
BackgroundRossant, J., & Tam, P. P. L. (2002) · Mouse Development · doi:10.1016/b978-012597951-1/50001-9
Cited by
Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore
Foley, E. A., & Kapoor, T. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3494 · Cited by 636
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer
Seshacharyulu, P., Pandey, P., Datta, K., & Batra, S. K. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.036 · Cited by 481
“Based on the mutations E64G and E64D, four different mouse strains were developed by Ruediger et al 2011: knock-in models E64D/ + and E64G/+; conditional Aα knock-out F5-6/+ with exon 5 and 6 floxed for Aα allele; and Δ5-6/+ was harboring exon 5 and 6 deletion in the Aα allele.”
BackgroundMethodInfluentialProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Phosphatase PP2A is requisite for the function of regulatory T cells
Apostolidis, S. A., Rodríguez-Rodríguez, N., Suárez-Fueyo, A., Dioufa, N., Ozcan, E., Crispín, J. C., Tsokos, M. G., & Tsokos, G. C. (2016) · Nature Immunology · doi:10.1038/ni.3390 · Cited by 238
Metadata
- Authors
- Ruediger, R., Ruiz, J., & Walter, G.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Walter, Gernot
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-09
- Volume
- 31
- Issue
- 18
- Pages
- 3832-3844
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3165721
- OpenAlex
- W2121528020
- Cited by
- 98
- References
- 86
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 7 · 2014: 8 · 2013: 6 · 2012: 7
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tobacco-Related Disease Research Program
- U.S. Public Health Service
- University of California, San Diego
- National Cancer Institute (R01CA118015)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- protein phosphatase 2A, tumor suppressor, lung cancer, cancer-associated mutations, benzopyrene, p53, knock-in mice, knockout mice, floxed mice, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Animals, Base Sequence, Benzopyrenes, Disease Models, Animal, Humans, Lung Neoplasms, Mice, Transgenic, Mutation, Incidence, Tumor Suppressor Protein p53, Point Mutation, Sequence Analysis, DNA, Mice, Knockout, Protein Isoforms, Protein Subunits, Tumor Suppressor Proteins, Mice, Protein Phosphatase 2, Gene Knock-In Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.